Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 MLN0264 in GCC-positive metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma
2014-000804-88Phase 2Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jul 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of indusatumab vedotin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Millennium Pharmaceuticals. Primary endpoint: Overall response rate (ORR). Started Jul 2014; status: terminated.
02
Drugs
indusatumab vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2014-000804-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000804-88.